These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9367495)

  • 1. Possible role of buspirone hydrochloride in smoking cessation.
    Bevelaqua FA
    Chest; 1997 Nov; 112(5):1445-6. PubMed ID: 9367495
    [No Abstract]   [Full Text] [Related]  

  • 2. Buspirone in the management of disruptive behaviors due to Huntington's disease and other neurological disorders.
    Bhandary AN; Masand PS
    Psychosomatics; 1997; 38(4):389-91. PubMed ID: 9217410
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased prolactin response to buspirone in chronic fatigue syndrome.
    Sharpe M; Clements A; Hawton K; Young AH; Sargent P; Cowen PJ
    J Affect Disord; 1996 Nov; 41(1):71-6. PubMed ID: 8938208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of the combination of sertraline with buspirone for smoking cessation. A randomized clinical trial in nondepressed smokers.
    Carrão JL; Moreira LB; Fuchs FD
    Eur Arch Psychiatry Clin Neurosci; 2007 Oct; 257(7):383-8. PubMed ID: 17902008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft-induced dyskinesias fail to respond to 5HT1A agonist in the long-term.
    Beaulieu-Boire I; Fasano A
    Mov Disord; 2015 May; 30(6):872-3. PubMed ID: 25758209
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of Low-Dose Buspirone for Restricted and Repetitive Behavior in Young Children with Autism Spectrum Disorder: A Randomized Trial.
    Chugani DC; Chugani HT; Wiznitzer M; Parikh S; Evans PA; Hansen RL; Nass R; Janisse JJ; Dixon-Thomas P; Behen M; Rothermel R; Parker JS; Kumar A; Muzik O; Edwards DJ; Hirtz D;
    J Pediatr; 2016 Mar; 170():45-53.e1-4. PubMed ID: 26746121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
    Mohammadi MR; Hafezi P; Galeiha A; Hajiaghaee R; Akhondzadeh S
    Acta Med Iran; 2012; 50(11):723-8. PubMed ID: 23292622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.
    McRae-Clark AL; Baker NL; Gray KM; Killeen TK; Wagner AM; Brady KT; DeVane CL; Norton J
    Drug Alcohol Depend; 2015 Nov; 156():29-37. PubMed ID: 26386827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buspirone to improve compliance in venlafaxine-induced movement disorder.
    Pavlovic ZM
    Int J Neuropsychopharmacol; 2004 Dec; 7(4):523-4. PubMed ID: 15383159
    [No Abstract]   [Full Text] [Related]  

  • 10. Buspirone in primary headaches.
    Pascual J; Berciano J
    Acta Neurol Scand; 1998 Feb; 97(2):142. PubMed ID: 9517866
    [No Abstract]   [Full Text] [Related]  

  • 11. Repurposing buspirone for drug addiction treatment.
    Le Foll B; Boileau I
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):251-3. PubMed ID: 23174122
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of fluoxetine and buspirone for treatment-refractory depersonalization disorder.
    Abbas S; Chandra PS; Srivastava M
    J Clin Psychiatry; 1995 Oct; 56(10):484. PubMed ID: 7559376
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of cerebellar ataxia with buspirone: a double-blind study.
    Trouillas P; Xie J; Adeleine P
    Lancet; 1996 Sep; 348(9029):759. PubMed ID: 8806320
    [No Abstract]   [Full Text] [Related]  

  • 14. Buspirone for anxiety and agitation in dementia.
    Cooper JP
    J Psychiatry Neurosci; 2003 Nov; 28(6):469. PubMed ID: 14631458
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of buspirone for treatment of cerebellar ataxia. An open-label study.
    Lou JS; Goldfarb L; McShane L; Gatev P; Hallett M
    Arch Neurol; 1995 Oct; 52(10):982-8. PubMed ID: 7575226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machado-Joseph disease/spinocerebellar ataxia 3 responsive to buspirone.
    Friedman JH
    Mov Disord; 1997 Jul; 12(4):613-4. PubMed ID: 9251088
    [No Abstract]   [Full Text] [Related]  

  • 17. Buspirone for stereotypic movements in elderly with cognitive impairment.
    Helvink B; Holroyd S
    J Neuropsychiatry Clin Neurosci; 2006; 18(2):242-4. PubMed ID: 16720804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological approaches to smoking cessation.
    Robbins AS
    Am J Prev Med; 1993; 9(1):31-3. PubMed ID: 8439435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy.
    Trouillas P; Xie J; Adeleine P; Michel D; Vighetto A; Honnorat J; Dumas R; Nighoghossian N; Laurent B
    Arch Neurol; 1997 Jun; 54(6):749-52. PubMed ID: 9193210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of buspirone on withdrawal symptoms associated with smoking cessation.
    Hilleman DE; Mohiuddin SM; Del Core MG; Sketch MH
    Arch Intern Med; 1992 Feb; 152(2):350-2. PubMed ID: 1739365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.